Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the...

What's Your Reaction?









